Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared a post on X:
“The best of ESMO 2024
Presidential Symposium III: Eyes to the Future!
Precision Immuno-Oncology for advanced NSCLC patients with PD-(L)1 inhibitor resistance
PIONeeR: Phase Ib/IIa clinical trial targeting identified resistance pathways
*Groundbreaking trial** to overcome ICI resistance!”
Source: Iván R. González/X
